Vyne Starts Phase 2b Trial Evaluating VYN201 for Vitiligo

 

• Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligo
• Top-line data from the 24-week double-blind portion of the trial expected in mid-2025
• “Repibresib” approved as the non-proprietary name for VYN201 by USAN

https://www.globenewswire.com/news-release/2025/01/06/3004503/0/en/VYNE-Therapeutics-Completes-Enrollment-in-Phase-2b-Trial-Evaluating-VYN201-for-the-Treatment-of-Nonsegmental-Vitiligo.html